Table 3.
SARS-CoV-2 specific monoclonal antibodies.
| Reference of isolation | Name | Isolation | Epitope information | Functionality | Clinical study level |
|---|---|---|---|---|---|
| Jones et al. [65] | Ly-CoV555 | SARS-CoV-2 convalescent patients | RBD- competing with ACE2 receptor | Neutralization | Phase 3 |
| Shi et al. [66] | CB-6 CB-6-LALA version is also known as JS016 or Ly-CoV016 or Etesevimab |
SARS-CoV-2 convalescent patients | RBD-epitope partially overlapping with ACE2 receptor | Neutralization | Phase 2/3 (Etesevimab) in combination therapy |
| Hansen et al. [67] | REGN10933 | Joined approach using both immunized humanized mice and B cells from convalescent patients | RBD- competing with ACE2 receptor | Neutralization ADCC ADCP |
Phase 3 |
| Rogers et al. [25] | CC12.1, CC6.29, CC6.30 | SARS-CoV-2 convalescent patients | RBD- competing with ACE2 receptor | Neutralization | Preclinical for therapeutic efficacy (for CC12.1) |
| Zost et al. [26] | COV2196, COV-2130 | SARS-CoV-2 convalescent patients | RBD- competing with ACE2 receptor-two different epitopes | Neutralization, synergistic activity | Preclinical for therapeutic and prophylactic efficacy |
| Cao et al. [68] |
BD-368-2 | SARS-CoV-2 convalescent patients | RBD- competing with ACE2 receptor | Neutralization |
Preclinical for therapeutic and prophylactic efficacy |
| Miersh et al. [69] | IgG 15033 | Human Fab phage library | RBD- competing with ACE2 receptor | Neutralization | NA |
| Gai et al. [70] | Nb11-59 | Phage library of camelid nanobodies | RBD- competing with ACE2 receptor | Neutralization, stable after nebulization | NA |
| Barnes et al. [71] | C121 and others | SARS-CoV-2 convalescent patients | RBD- competing with ACE2 receptor | Neutralization | NA |
| Hansen et al. [67] | REGN10987 | Joined approach using both immunized humanized mice and B cells from convalescent patients | RBD- not competing with ACE2 receptor | Neutralization ADCC ADCP |
Phase 3 |
| Wu et al. [72] | n3088, n3031 and others | naive library of human 3 66*01 human VH genes | RBD- not competing with ACE2 receptor | Neutralization | NA |
| Barnes et al. [71] | C135 and others | SARS-CoV-2 convalescent patients | RBD- not competing with ACE2 receptor | Neutralization | NA |
| Chi et al. [73] | 4A8 | SARS-CoV-2 convalescent patients | S1 NTD | Neutralization | NA |
| Liu et al. [74] | 5-7, 5-24, 2-17 and others | SARS-CoV-2 convalescent patients | S1 NTD | Neutralization | NA |
| Liu et al. [74] | 2-43 | SARS-CoV-2 convalescent patients | Quaternary epitope of S1 trimer | Neutralization | NA |
Color of lines distinguishes mAbs for the region of S-protein that is recognized.